Cellectar Biosciences, Inc. (CLRB) News
Track canonical SquawkNews coverage tagged to CLRB, Cellectar Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Cellectar Biosciences, Inc. (CLRB) Posts 79% Major Response in WM Subset
Cellectar Biosciences reported a 79.2% major response rate, 87.5% overall response, and duration exceeding 16 months in a Phase 2 CLOVER WaM subset treated immediately post-BTKi, and plans a Phase 3 confirmatory trial wi
CENTRAL_BANK | Sep 29, 2026, 11:33 AM UTC
L
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi TherapyData Furth
CENTRAL_BANK | Sep 29, 2026, 11:33 AM UTC